Toshima-ku, Japan

Shuhei Kashiwa

USPTO Granted Patents = 3 

 

 

Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 4(Granted Patents)


Company Filing History:


Years Active: 2011-2012

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Shuhei Kashiwa

Introduction

Shuhei Kashiwa is a notable inventor based in Toshima-ku, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of therapeutic agents for various mental and physical health conditions. With a total of 3 patents to his name, Kashiwa's work is recognized for its potential impact on healthcare.

Latest Patents

Kashiwa's latest patents focus on phenylpyrazole derivatives. These inventions provide prophylactic or therapeutic agents for a range of conditions, including dementia, Alzheimer's disease, attention-deficit hyperactivity disorder, schizophrenia, eating disorders, obesity, diabetes, hyperlipidemia, sleep disorders, narcolepsy, sleep apnea syndrome, circadian rhythm disorder, depression, and allergic rhinitis. The patents detail a phenylpyrazole derivative represented by a specific formula, which may include pharmaceutically acceptable salts.

Career Highlights

Shuhei Kashiwa is currently associated with Taisho Pharmaceutical Co., Ltd., where he continues to innovate and contribute to the pharmaceutical industry. His work is characterized by a commitment to addressing complex health issues through scientific research and development.

Collaborations

Kashiwa has collaborated with esteemed colleagues, including Toshio Nakamura and Makoto Tatsuzuki. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.

Conclusion

Shuhei Kashiwa's contributions to the field of pharmaceuticals through his innovative patents demonstrate his dedication to improving health outcomes. His work continues to inspire advancements in therapeutic agents that address critical health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…